<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05079113</url>
  </required_header>
  <id_info>
    <org_study_id>CASE1619</org_study_id>
    <nct_id>NCT05079113</nct_id>
  </id_info>
  <brief_title>Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting</brief_title>
  <official_title>Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Adjuvant Melanoma Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To generate meaningful data regarding ctDNA that would infer risk of recurrence in stage III&#xD;
      melanoma patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cancer cells harbor and can acquire potentially hundreds of mutations, many of whom are found&#xD;
      in the ctDNA. Circulating tumor DNA (ctDNA) holds the promise for the 50% of participants who&#xD;
      do not need adjuvant therapies - participants could be monitored to ensure no increase in&#xD;
      ctDNA. Participants treated could then be followed for the earliest possible blood level&#xD;
      signs of recurrence (incr. ctDNA) and more quickly be switched to more effective therapies.&#xD;
      Further, the treating physician could hold therapy until the first signs of ctDNA based&#xD;
      recurrence for those participants that would benefit.&#xD;
&#xD;
      Blood sample from a biobank will be used to identify to monitor ctDNA. These blood samples&#xD;
      were drawn at baseline, 3 months, 6 months and 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identify a pattern for gene recognition of cancer recurrence earlier than standard of care.</measure>
    <time_frame>samples taken at baseline, 3 months, 6 months and 18 months.</time_frame>
    <description>Genomic sequencing of 40+ ctDNA genes will be analyzed to identify genetic alterations correlating with the development of recurrence in melanoma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analyze the genetic pathway associated with cancer recurrence and biologic information.</measure>
    <time_frame>samples taken at baseline, 3 months, 6 months and 18 months.</time_frame>
    <description>The sequencing data will be analyzed against established determinants of cancer biology in clinically relevant melanoma variants identified via analysis of The Cancer Genome Atlas database.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Stage III Melanoma</condition>
  <condition>Stage IV Cutaneous Melanoma</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Retrospectively collected blood samples from a biobank.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Retrospective biobanking samples collected at baseline, 3 months, 6 months and 18 months.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18&#xD;
&#xD;
          -  Confirmed fully resected Stage IIIb-IV cutaneous melanoma; including patients treated&#xD;
             neoadjuvantly within three months prior to resection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        • Treatment plan inconsistent with the standard of care systemic adjuvant therapies 4.0&#xD;
        Study Design&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Gastman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brian Gastman, MD</last_name>
    <phone>1-866-223-8100</phone>
    <email>TaussigResearch@ccf.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Gastman, MD</last_name>
      <phone>866-223-8100</phone>
      <email>TaussigResearch@ccf.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 4, 2021</study_first_submitted>
  <study_first_submitted_qc>October 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

